Journal Articles on Mesothelioma: 'Treatment' Category
August 19th, 2008. Primary malignant mesothelioma developed in liver
A local recurrence was noted 15 months after surgery, which was treated by radiofrequency ablation. At 23 months after initial surgery, locally recurrent masses with direct invasion of the diaphragm and a solitary intrahepatic metastasis were noted, which was treated by partial excision of the diaphragm with intraoperative RFA after transarterial chemoembolization.
August 14th, 2008. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma
Conclusions: These results indicated that p21 might play an important role in chemosensitivity to anticancer agents, and the suppression of its expression might be a potential therapeutic target for MPM.
August 14th, 2008. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction
Pemetrexed is an antifolate drug, approved for treatment of metastatic non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). We present a case of AGEP caused by pemetrexed, and a recurrence of this eruption after re-introduction of pemetrexed despite use of corticosteroids.
August 9th, 2008. Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors
The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
August 8th, 2008. Novel Functional View of the Crocidolite Asbestos-Treated A549 Human Lung Epithelial Transcriptome Reveals an Intricate Network of Pathways with Opposing Functions
Conclusions: Our analyses demonstrate the power of combining a statistically robust, comprehensive dataset and a functional network genomics approach to 1) identify and explore relationships between genes of known importance 2) identify novel candidate genes, and 3) observe the complex interplay between genes/gene products that function in seemingly different processes. This study represents the first function-based global approach toward understanding the response of human lung epithelial cells to the carcinogen crocidolite. Importantly, our investigation paints a much broader landscape for the crocidolite response than was previously appreciated and reveals novel paths to study. Our graphical representations of the function-based global network will be a valuable resource to model new research findings.
August 7th, 2008. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma
Conclusion: This is the first study of the relationship between HtrA1 expression and survival of mesothelioma patients. The data obtained strongly indicate the utilization of HtrA1 expression as a prognostic parameter for mesothelioma and suggest this serine protease as a possible molecular target for the treatment of malignant mesotheliomas.
August 5th, 2008. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis
In spite of the need for more high quality phase III studies, there is now a consensus among many surgical oncology experts throughout the world about the use of this new treatment strategy as standard care for colorectal cancer patients with PC. This review summarizes the current status and possible progress in future.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 5th, 2008. Surgical treatment of peritoneal carcinomatosis with reduction surgery and perioperative chemotherapy
An organ resection should thus be performed. The patient is then referred to a specialized center, either within the ten days following the procedure, or after three months, most of the time after an adjuvant therapy.
August 5th, 2008. Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
In several instances, these engineered ribonucleases exhibit greater cytotoxicity in vitro than does ONC. Herein, we review the biochemical characteristics of RI ribonuclease complexes and progress towards the development of mammalian ribonuclease-based chemotherapeutics through the elicitation of RI-evasion.
August 5th, 2008. Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes
Onconase and Amphinase are highly cationic molecules and their preferential toxicity towards cancer cells (having distinctly higher negative charge compared to normal cells) may depend on increased binding efficiency to the cell surface by electrostatic interactions. Here we will discuss the structures of Onconase and Amphinase and the molecular basis for their enzymatic and anticancer functions.
August 5th, 2008. Antibody-onconase conjugates: cytotoxicity and intracellular routing
Antibody-onconase conjugates are effective in preclinical models, cause little non-specific toxicities in mice and have favorable formulation properties. Understanding the reason for their potency coupled with understanding novel RNA-based mechanisms of tumor cell death will lead to improved variations of targeted onconase.
August 5th, 2008. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy
Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anti-cancer therapeutics.
August 2nd, 2008. MET as a target for treatment of chest tumors
These drugs function at a variety of steps within the HGF-MET pathway, including MET expression at the RNA or protein level, the ligand-receptor interaction, and tyrosine kinase function. This paper will review the structure, function, mechanisms of tumorigenesis, and potential for therapeutic inhibition of the MET receptor in lung cancer and mesothelioma.
July 29th, 2008. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy
Conclusion: If a patient with epithelioid MPM is fit enough to tolerate a thoracotomy then macroscopic clearance of the tumour is the preferred option as part of a multimodality regime including chemotherapy.
Posted in Chemotherapy, Epithelioid, Full Archive, Pleurectomy/decortication, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 29th, 2008. Targeted therapy–possible new therapeutic option for malignant mesothelioma?
Molecular screening methods have revealed profound differences in the driving mechanisms of the variously differentiated mesothelioma cells. Characterization of these differences has made it possible to identify novel drug targets which are effective for both phenotypes.
July 26th, 2008. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT)
In each case, the tumors regressed or remained stable in size for 3–6 months following BNCT. No acute or late adverse events higher than grade 2 were observed.
July 26th, 2008. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin
Conclusions: Doxorubicin shows characteristics favorable for intracavitary administration with sequestration of doxorubicin in cancer nodules.
Posted in Chemotherapy, Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Intrapleural Chemotherapy, Peritoneal (Abdominal Mesothelioma), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 23rd, 2008. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis
Conclusions: An indwelling pleural catheter is a safe alternative for patients with malignant pleural effusion unsuitable for talc pleurodesis. In some, pleural fusion may be achieved.
July 22nd, 2008. A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
Conclusions: Tetrathiomolybdate has antiangiogenic effects in malignant pleural mesothelioma patients after resection of gross disease, and exhibits minimal toxicity and comparable efficacy to previous multimodality trials. Tetrathiomolybdate should be evaluated for efficacy in combination with standard malignant pleural mesothelioma regimens, as well as for postsurgical maintenance therapy.
July 22nd, 2008. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
Conclusion: The combination of pemetrexed plus gemcitabine was active in patients with MPeM with a notably high incidence of neutropenia. Median TTPD and OS seem promising. This regimen may provide an alternative to standard therapies, especially for patients who cannot tolerate a platinum-based regimen.
|
|  |
